Ovarian Cancer Early Detection Assay
Ovarian Cancer
Pre-clinicalActive
Key Facts
About GenEndeavor
GenEndeavor is a private, pre-revenue diagnostics company developing a proprietary Non-Enzymatic Amplification Technologies (NEAT) platform aimed at revolutionizing molecular diagnostics. The company's initial focus is on creating an accessible diagnostic tool for the early detection of ovarian cancer, with a broader vision to impact genetic diseases, infectious diseases like tuberculosis, and agricultural trait screening. Led by founder and CEO Ricardo Mancebo, the company is actively engaging with investors and global partners to advance its technology and pipeline.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |
| High Internalization ADC | Lytica Therapeutics | Preclinical |